A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid«) Regimen or a Sequential Azacitidine (Vidaza«) Plus Lenalidomide (Revlimid«) Regimen Versus an Azacitidine (Vidaza«) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ?65 years with newly-diagnosed acute myeloid leukemia (AML).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Azacitidine
- drug : Lenalidomide
- other : Best Supportive Care (BSC)
Phase: Phase 2
Ages Eligible For Study:
- Newly diagnosed acute myeloid leukemia (AML), AML with antecedent hematologic disorder or therapy-related AML - Male or female subjects aged ? 65 - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - White blood cell (WBC) count ? 10 x 10?/L at screening